Manufacturing Scale Lannett's in-house capacity is robust, with 3.5 billion oral solid doses and 2.0 million liters of liquids annually, enabling end-to-end contract manufacturing, toll production, and scalable supply for generic and proprietary product lines.

Biosimilars Pipeline Active pursuit of biosimilars, including insulin glargine and insulin aspart programs, along with authorized generic evothyroxine capsules and device integration partnerships with Ypsomed, signals opportunities for co-development, fill-finish, packaging, and device-enabled collaborations.

Strategic Partnerships Strategic alliances with Societal CDMO and Ypsomed demonstrate openness to licensing, technology transfer, and supply partnerships across small molecules and biologics, presenting a fertile path for co-development, licensing deals, or multi-party manufacturing arrangements.

Compliance Opportunity Recent settlements related to generic price practices highlight regulatory scrutiny and reputational risk in the sector; position Lannett as a partner focused on transparent pricing, compliance support, and robust supply-chain governance to reassure customers and distributors.

Growth & M&A Financial context shows mid-market scale with revenue in the hundreds of millions and notable M&A interest (2025 acquisition talks); buyers and distributors may seek capacity expansion, product pipeline access, or strategic partnerships to accelerate time-to-market and portfolio diversification.